soul trial oral semaglutide cardiovascular outcomes results 2024 nejm Canadian Perspectives 2025 Whiteboard on the Semaglutide cardiovascular outcomes align more

[1] [2] This triple-receptor mechanism distinguishes it from currently approved agents such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GIP/GLP-1 agonist)

The bigger question is not just whether this drug works

Cardiovascular symptoms : Chest pain, severe palpitations, or shortness of breath warrant urgent assessment

See If You Qualify For an Ozempic Lawsuit What Medical and Legal Experts Say About Ozempic Injuries Ozempic Vision Loss and Blindness Lawsuits Lawyers are investigating Ozempic vision loss and blindness lawsuits

Handling and Storage Store EP-3 (R) as a lyophilized powder at -4F (-20C) in a tightly sealed vial, protected from humidity and direct light until required for laboratory research